Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    64,481.56
    +961.25 (+1.51%)
     

  • CMC Crypto 200

    1,386.36
    +73.73 (+5.96%)
     

  • S&P 500

    4,989.51
    -21.61 (-0.43%)
     

  • Dow

    37,938.78
    +163.40 (+0.43%)
     

  • Nasdaq

    15,414.32
    -187.18 (-1.20%)
     

  • Gold

    2,406.70
    +8.70 (+0.36%)
     

  • Crude Oil

    82.87
    +0.14 (+0.17%)
     

  • 10-Yr Bond

    4.6060
    -0.0410 (-0.88%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

How Minerva Neurosciences (NERV) Stock Stands Out in a Strong Industry

Zacks Equity Research
·2-min read

One stock that might be an intriguing choice for investors right now is Minerva Neurosciences, Inc. NERV. This is because this security in the Medical - Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Drugs space as it currently has a Zacks Industry Rank of 32 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Minerva Neurosciences is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Minerva Neurosciences, Inc Price and Consensus

Minerva Neurosciences, Inc Price and Consensus
Minerva Neurosciences, Inc Price and Consensus

Minerva Neurosciences, Inc price-consensus-chart | Minerva Neurosciences, Inc Quote

ADVERTISEMENT

In fact, over the past month, current quarter estimates have narrowed from a loss of 31 cents per share to a loss of 25 cents per share, while current year estimates have narrowed from a loss of $1.16 per share to a loss of $1.01 per share. This has helped NERV to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Minerva Neurosciences. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Stocks to Soar Past the Pandemic: In addition to the companies you learned about above, we invite you to learn about 5 cutting-edge stocks that could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of the decade.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Minerva Neurosciences, Inc (NERV) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research